{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:26:16Z","timestamp":1789017976706,"version":"build-2803163510"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:00:00Z","timestamp":1728432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Pharmacogenetics (PGx) holds promise for optimizing psychotropic medication use, with\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      and\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      identified as key genes in antidepressant treatment. However, few studies have explored the genetic variants of these genes in real-world settings for patients experiencing ineffectiveness or adverse drug reactions (ADRs) to antidepressants.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This case series includes 40 patients who underwent PGx testing due to antidepressant ineffectiveness or ADRs between June 2020 and April 2022. We describe the patients' demographic, clinical, and genetic characteristics and assess the value of PGx testing based on feedback from their psychiatrists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most common diagnoses were major depressive disorder (60.0%) and post-traumatic stress disorder (30.0%). Ineffectiveness was reported in 65.0% of patients, ADRs in 2.5%, and both in 32.5%. The antidepressants involved included SSRIs (45.0%), SNRIs (27.5%), atypical antidepressants (20.0%), and tricyclics (17.5%). Only 17.5% of patients had normal\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      and\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      metabolic activity. Actionable genetic variants were identified in 22.0% of\n                      <jats:italic>CYP2D6<\/jats:italic>\n                      \/\n                      <jats:italic>CYP2C19<\/jats:italic>\n                      -antidepressant-response pairs. PGx recommendations were followed in 92.7% of cases, with significant improvement in ADRs reported in 71.4% of patients and efficacy improvement in 79.5%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Our findings suggest that PGx testing can guide prescribing decisions for patients with antidepressant ineffectiveness or ADRs. The relatively high prevalence of genetic variants affecting pharmacokinetics supports the broader adoption of PGx testing in psychiatric practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1440523","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:53:09Z","timestamp":1728435189000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacogenetics testing for poor response to antidepressants: a transnosographic case series"],"prefix":"10.3389","volume":"15","author":[{"given":"Marie-Agn\u00e8s","family":"Lorvellec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Sipahimalani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Lahutte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Delacour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emeric","family":"Saguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.encep.2021.12.008","article-title":"Cytochrome pharmacogenetics applied to the prescription of antidepressants: instructions for use","volume":"48","author":"Baldacci","year":"2022","journal-title":"Encephale"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.3390\/pharmaceutics15112540","article-title":"Pharmacogenetic guidelines for psychotropic drugs: optimizing prescriptions in clinical practice","volume":"15","author":"Baldacci","year":"2023","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/S1461145710001434","article-title":"Evidence-based pharmacological treatment of generalized anxiety disorder","volume":"14","author":"Baldwin","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"814981","DOI":"10.3389\/fpubh.2022.814981","article-title":"Prevalence of anxiety and depression among the general population in africa during the COVID-19 pandemic: a systematic review and meta-analysis","volume":"10","author":"Bello","year":"2022","journal-title":"Front. Public Health"},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/pgs-2018-0142","article-title":"Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials","volume":"20","author":"Bousman","year":"2019","journal-title":"Pharmacogenomics"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/cpt.2903","article-title":"Clinical pharmacogenetics implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman","year":"2023","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.24966\/PDA-0150\/100001","article-title":"Pharmacogenomics of antidepressants","volume":"1","author":"Cacabelos","year":"2015","journal-title":"J. Psychiatr. Depress Anxiety"},{"key":"B8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40262-014-0162-1","article-title":"Impact of cytochrome P450 2C19 polymorphisms on citalopram\/escitalopram exposure: a systematic review and meta-analysis","volume":"53","author":"Chang","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12888-023-04581-7","article-title":"Prevalence and economic burden of depression and anxiety symptoms among Singaporean adults: results from a 2022 web panel","volume":"23","author":"Chodavadia","year":"2023","journal-title":"BMC Psychiatry"},{"key":"B10","unstructured":"CPIC guideline for selective serotonin reuptake inhibitors and CYP2D6 and CYP2C192023"},{"key":"B11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/00048674221079740","article-title":"Changes in antidepressant use in Australia: a nationwide analysis (2015-2021)","volume":"57","author":"de Oliveira Costa","year":"2023","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"B12","article-title":"The flockhart cytochrome P450 drug-drug interaction table","volume-title":"Division of clinical pharmacology","author":"Flockhart","year":"2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"000","DOI":"10.14218\/JERP.2022.00054","article-title":"A collaborative approach in pharmacogenetic testing: actionable genotypes of antidepressants and their avoidance in a retrospective study","volume":"8","author":"Hahn","year":"2023","journal-title":"J. Explor. Res. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.9758\/cpn.2018.16.4.469","article-title":"A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial","volume":"16","author":"Han","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1192\/bjp.bp.114.148551","article-title":"Pharmacotherapy for post-traumatic stress disorder: systematic review and meta-analysis","volume":"206","author":"Hoskins","year":"2015","journal-title":"Br. J. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1002\/cpt.1322","article-title":"Standardized biogeographic grouping system for annotating populations in pharmacogenetic research","volume":"105","author":"Huddart","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/0269881111414451","article-title":"CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP","volume":"26","author":"Huezo-Diaz","year":"2012","journal-title":"J. Psychopharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.tpj.6500285","article-title":"Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity","volume":"5","author":"Ingelman-Sundberg","year":"2005","journal-title":"Pharmacogenomics J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1176\/appi.ajp.2017.17050550","article-title":"Impact of CYP2C19 genotype on escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients","volume":"175","author":"Juki\u0107","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1080117","DOI":"10.3389\/fphar.2023.1080117","article-title":"The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses","volume":"14","author":"Kee","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41398-021-01417-4","article-title":"Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample","volume":"11","author":"Lunenburg","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3389\/fpsyt.2019.00690","article-title":"The three ps: psychiatry, pharmacy, and pharmacogenomics, a brief report from New Zealand","volume":"10","author":"Maggo","year":"2019","journal-title":"Front. Psychiatry"},{"key":"B23","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1001\/jamapsychiatry.2020.3643","article-title":"Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta-analysis","volume":"78","author":"Milosavljevic","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.7860\/JCDR\/2013\/4985.3041","article-title":"Adverse drug reaction monitoring of antidepressants in the psychiatry outpatients department of a tertiary care teaching hospital","volume":"7","author":"Mishra","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1176\/appi.ps.201300059","article-title":"A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996-2013","volume":"65","author":"Mrazek","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"B26","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jama.2022.9805","article-title":"Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME care randomized clinical trial","volume":"328","author":"Oslin","year":"2022","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"P\u00e9rez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"B28","unstructured":"Gene-specific information Tables for CYP2C192015"},{"key":"B29","unstructured":"Gene-specific information Tables for CYP2D62017"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1267294","DOI":"10.3389\/fphar.2023.1267294","article-title":"Utility of pharmacogenetic testing to optimise antidepressant pharmacotherapy in youth: a narrative literature review","volume":"14","author":"Roberts","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/tpj.2009.50","article-title":"The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients","volume":"10","author":"Schenk","year":"2010","journal-title":"Pharmacogenomics J."},{"key":"B33","volume-title":"Antidepressants","author":"Sheffler","year":"2022"},{"key":"B34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.psychres.2018.12.053","article-title":"Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?","volume":"271","author":"Solomon","year":"2019","journal-title":"Psychiatry Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte--an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B36","volume-title":"Jamovi. (Version 2.4)","year":"2023"},{"key":"B37","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B38","unstructured":"Depression and other common mental disorders: global health estimates2017"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440523\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T00:53:12Z","timestamp":1728435192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1440523\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,9]]},"references-count":38,"alternative-id":["10.3389\/fphar.2024.1440523"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1440523","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,9]]},"article-number":"1440523"}}